Fortress Biotech, Inc. (FBIO)
NASDAQ: FBIO · Real-Time Price · USD
2.840
-0.090 (-3.07%)
Aug 25, 2026, 1:02 PM EDT - Market open
Fortress Biotech Employees
Fortress Biotech had 78 employees as of December 31, 2025. The number of employees decreased by 23 or -22.77% compared to the previous year.
Employees
78
Change (1Y)
-23
Growth (1Y)
-22.77%
Revenue / Employee
$877,769
Profits / Employee
$1,325,218
Market Cap
94.72M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 78 | -23 | -22.77% |
| Dec 31, 2024 | 101 | -85 | -45.70% |
| Dec 31, 2023 | 186 | -1 | -0.53% |
| Dec 31, 2022 | 187 | 14 | 8.09% |
| Dec 31, 2021 | 173 | 62 | 55.86% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Adicet Bio | 102 |
| Pelthos Therapeutics | 92 |
| Acrivon Therapeutics | 76 |
| ImmuCell | 73 |
| Biomea Fusion | 37 |
| Cue Biopharma | 29 |
| Tenax Therapeutics | 16 |
| Cognition Therapeutics | 14 |
FBIO News
- 11 days ago - Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 12 days ago - Fortress Biotech Earnings Call Transcript: Q2 2026 - Transcripts
- 12 days ago - Fortress Biotech Earnings release: Q2 2026 - Filings
- 12 days ago - Fortress Biotech Quarterly report: Q2 2026 - Filings
- 12 days ago - Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 20 days ago - Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026 - GlobeNewsWire
- 4 weeks ago - Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $130 Million Series B Financing - GlobeNewsWire
- 2 months ago - Fortress Biotech Transcript: AGM 2026 - Transcripts